Evidence map›Paper›PMID 35185775›Full record

ArticleFrontiers in neurology2022

Is the Phenotype Designation by PSP-MDS Criteria Stable Throughout the Disease Course and Consistent With Tau Distribution?

Javier Sánchez-Ruiz de Gordoa, Victoria Zelaya, Paula Tellechea-Aramburo, Blanca Acha, Miren Roldán, Carlos López-Molina, Valle Coca, Arkaitz Galbete, Maite Mendioroz, M Elena Erro

Abstract read
In one paragraph

Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Observational
  3. [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  4. Article
  5. Prospective Multicenter Evaluation of the MDS "Suggestive of PSP" Diagnostic Criteria.Movement disorders : official journal of the Movement Disorder Society · 2025
    Observational
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Clinical, cognitive, and morphometric profiles of progressive supranuclear palsy phenotypes.Journal of neural transmission (Vienna, Austria : 1996) · 2023
    Article
  12. Clinical Spectrum of Tauopathies.Frontiers in neurology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Javier Sánchez-Ruiz de GordoaDepartment of Neurology, Hospital Universitario de Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Victoria ZelayaDepartment of Pathology, Hospital Universitario de Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Paula Tellechea-AramburoDepartment of Neurology, Hospital Universitario de Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Blanca AchaNeuroepigenetics Laboratory-Navarrabiomed, Hospital Universitario de Navarra, Universidad Pública de Navarra (UPNA), Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Miren RoldánNeuroepigenetics Laboratory-Navarrabiomed, Hospital Universitario de Navarra, Universidad Pública de Navarra (UPNA), Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Carlos López-MolinaDpto. Automática y Computación, Universidad Pública de Navarra (UPNA), Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Valle CocaNavarrabiomed Brain Bank, Hospital Universitario de Navarra, Universidad Pública de Navarra (UPNA), Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Arkaitz GalbeteNavarrabiomed, Universidad Pública de Navarra (UPNA), REDISSEC, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Maite MendiorozDepartment of Neurology, Hospital Universitario de Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
M Elena ErroDepartment of Neurology, Hospital Universitario de Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe MDS-PSP criteria have shown high sensitivity for the PSP diagnosis, but do not discriminate the phenotype diversity. Our purpose was to search for anatomopathological differences among PSP phenotypes resulting from the application of the MDS-PSP criteria comparing with the previous ones.

methodsThirty-four PSP cases from a single brain bank were retrospectively classified according to the criteria used by Respondek et al. in 2014 and the PSP-MDS criteria at 3 years (MDS-3y), 6 years (MDS-6y) and at the last clinical evaluation before death (MDS-last). Semiquantitative measurement of total, cortical and subcortical tau load was compared. For comparative analysis, PSP-Richardson syndrome and PSP postural instability were grouped (PSP-RS/PI) as well as the PSP atypical cortical phenotypes (PSP-Cx).

resultsApplying the Respondek's criteria, PSP phenotypes were distributed as follow: 55.9% PSP-RS/PI, 26.5% PSP-Cx, 11.8% PSP-Parkinsonism (PSP-P), and 5.9% PSP-Cerebellum. PSP-RS/PI and PSP-Cx had a higher total tau load than PSP-P; PSP-Cx showed a higher cortical tau load than PSP-RS/PI and PSP-P; and PSP-RS/PI had a higher subcortical tau load than PSP-P. Applying the MDS-3y, MDS-6y and MDS-last criteria; the PSP-RS/PI group increased (67.6, 70.6 and 70.6% respectively) whereas the PSP-Cx group decreased (8.8, and 8.8 and 11.8%). Then, only differences in total and subcortical tau burden between PSP-RS/PI and PSP-P were observed.

interpretationAfter the retrospective application of the new MDS-PSP criteria, total and subcortical tau load is higher in PSP-RS/PI than in PSP-P whereas no other differences in tau load between phenotypes were found, as a consequence of the loss of phenotypic diversity.

Indexed as

clinical-pathological correlationphenotypesprogressive supranuclear palsy (PSP)PSP-MDS criteriatauopathiestau protein load

Identifiers

PMID35185775
PMCPMC8850262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.